Chris Tam, PhD
Dr. Chris Tam, co-founder of Integrated Nanotherapeutics, obtained her B.Sc. in Biochemistry from McGill University and her Ph.D. in Cell Biology from the University of Alberta. She has extensive research experience in biochemistry, cell biology as well as drug design and development. Prior to founding Integrated Nanotherapeutics, Chris worked at the Life Sciences Institute at the University of British Columbia, where she was part of the supervisory team for graduate and post-graduate scientists working on the development of lipid nanoparticles for the delivery of macromolecule drugs, such as siRNA and DNA, as well as small molecule drugs. Many of these lipid nanoparticle drug formulations have direct implication for the treatment of a wide range of diseases including cancers, hematological diseases, osteoporosis, autoimmune disorders and diabetes. Chris is the leader of Integrated nanotherapeutics.
Ying Tam, PhD
Dr. Ying Tam, co-founder of Integrated Nanotherapeutics, obtained his B.Sc., M.Sc. and Ph.D. in Biology from the University of Waterloo, Ontario. He has held a number of senior academic and industry positions in the Department of Hematology/Oncology, Faculty of Medicine, Rush-Presbyterian-St. Luke’s Medical Center in Chicago, USA, as well as Tekmira Pharmaceuticals and Acuitas Therapeutics, Vancouver, Canada. Ying has over 20 years of experience overseeing all stages of drug development, from preclinical research to clinical studies and business development. In both academic and industry positions, he has lead research teams developing novel liposomal nucleic acid drugs. Ying has established and overseen a number of collaborations and industry partnerships over the years. Dr. Tam is an author on over 45 manuscripts and 7 patents.
Board of Directors
Pieter Cullis, PhD
Chairman & Scientific Advisor
Dr. Pieter Cullis, co-founder of Integrated Nanotherapeutics and Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia, has been responsible for fundamental advances in the generation, loading and targeting of lipid nanoparticle (LNP) systems for intravenous delivery of small molecule drugs and genetic drugs. These efforts have led to three drugs (Abelcet, Myocet and Marqibo) that have been approved by regulatory agencies in the U.S. and Europe for the treatment of cancer and its complications and seven more (Alocrest, Brakiva, LNP-Ciprofloxacin, MNK-010, ALN-VSP, ALN-PCS, ALN-TTR) that are in clinical trials. Dr. Cullis has also been extensively involved in founding companies to commercialize technologies. He co-founded and served on the board of the Canadian Liposome Company, Inex Pharmaceuticals (now Tekmira Pharmaceuticals), Northern Lipids Inc., Lipex Biomembranes Inc., and, most recently, Acuitas Pharmaceuticals and Precision NanoSystems. In addition, he co-founded and was Scientific Director of the Centre for Drug Research and Development (CDRD). Dr. Cullis is also the co-founder of the BC Personalized Medicine Initiative (PMI). He has published over 300 papers and holds over 45 separate patents.
Marco Ciufolini, PhD
Director & Scientific Advisor
Dr. Marco Ciufolini, co-founder of Integrated Nanotherapeutics, holds the position of Professor and Canada Research Chair in synthetic organic chemistry in the Department of Chemistry at the University of British Columbia. He is a leading expert in organic chemistry with significant expertise in medicinal chemistry. He has various awards to his credit, including most recently, the 2013 Canadian Society for Chemistry R. U. Lemieux Prize. He is a co-founder of AB Science, SA. This company was created to commercialize one of the drugs he invented: the tyrosine kinase inhibitor, Masitinib®, which is in Phase III trials for various cancerous and degenerative conditions. He is also a co-founder of Chrysalon SA, and Global Pharmaceutical Consulting, Inc., and is a consultant in medicinal and process chemistry for several pharmaceutical laboratories in the US and in Europe. Dr. Ciufolini's research on new reactions for the assembly of nitrogen-containing compounds and on the total synthesis of nitrogenous natural products is described in over 130 peer-reviewed articles and 7 book chapters. He is also an inventor on 30 patents.
Bruce Verchere, PhD
Director & Scientific Advisor
Dr. Bruce Verchere is a co-founder of Integrated Nanotherapeutics, Professor in the Departments of Pathology & Laboratory Medicine and Surgery at the University of British Columbia, head of the Diabetes Research Program at the Child & Family Research Institute (CFRI) at BC Children’s Hospital, and the Irving K Barber Chair in Diabetes Research. His specializes in the development of therapeutic approaches for enhancing beta cell survival and function in diabetes and islet transplants. He has published over 100 manuscripts in the field of islet biology and diabetes. Dr. Verchere was awarded the UBC Outstanding Young Alumnus award in 2000, the Canadian Diabetes Association Young Scientist award in 2006, and in 2012 received a Queen Elizabeth II Diamond Jubilee Medal for diabetes research and service. Dr. Verchere is chair of the CIHR Diabetes Obesity Lipid and Lipoprotein Disorders and JDRF Islet Biology & Transplantation Training and Innovative grant review panels, and a member of the national research council and national board of directors of the Canadian Diabetes Association He has served on the editorial boards of Diabetes and the Canadian Journal of Diabetes and is currently on the editorial board of Endocrinology, and associate editor of the journal Islets.